99), SVT three.0 (6/199). Apixaban 63.8 (127/199), Rivaroxaban 36.2 (72/199). Doses: (138/199)

99), SVT three.0 (6/199). Apixaban 63.8 (127/199), Rivaroxaban 36.2 (72/199). Doses: (138/199) 69.three complete doses, (61/199) 30.7 half doses. Bleedings 5.52 (11/199), 0.5 major (1/199), five.02 minor (10/199). Non substantial variations in Anti Xa between CCR4 Antagonist custom synthesis bleeding and non bleeding groups. Recurrence: 1.0 (2/199). Anti Xa U/ml: Mean +/- SD: Stop by 1 APIXABAN (N = 127) trough 87.6 +/- 58.2; peak 185.4 two.9; Pay a visit to 2 (N = 70); trough 102.2 75.two; peak 196.six 98.five RIVAROXABAN Pay a visit to 1 (N = 72): trough 34.7 17.six, peak 185.four 82.9, Stop by 2 (N = 30): trough 34.0 17.5, peak 224.0 77.8. Rivaroxaban larger anti-Xa at peak in Stop by 2, P = 0.035. In between Argentina and Mexico, Apixaban trough at 5 mg/12 hrs showed distinction (P = 0.023). Not other statistically significant differences amongst countries were located. Conclusions: Anti Xa values obteined had been in accordance with information has been published (1,two). We observed an interinvidual variation within the second Rivaroxaban peak. This can be the very first Latin American cooperative study focused on the analysis of your population treated with DOACs.PB1268|Nationwide Children’s Hospital Pediatric and Adult Comprehensive Anticoagulation Program: A Report on its Anticoagulation Management and Clinical OutcomesPB1267|International Multicentric Study: Laboratory in Individuals Treated with Apixaban or Rivaroxaban in Latin America (Larila): Final Final results E. Cortina1,two; D. Garcia3,two; G. Conte four,2; M.C. Guillermo5,2; M. C eo four,2; P. Turcatti5,two; R. Izaguirre1,1V. Rodriguez; J. Stanek; J. Giver; A. Dunn; A. Sankar; K. Monda; J. Canini; B. Kerlin Nationwide Children’s Hospital/The Ohio State University, Columbus, Usa Background: Devoted anticoagulation applications have demonstrated improvement in patients’ anticoagulation management and outcomes. Our anticoagulation system, established in 2014, is unique because it supplies complete care to pediatric and adult patients expanding diverse geographical places in the state of Ohio. Aims: (1) Compare the influence of an anticoagulation program preand post-implementation, around the top quality of anticoagulation as measured by time in therapeutic range ( TTR) and compliance. (two) To assess clinical outcomes (bleeding and thrombosis complications) prior and following anticoagulation plan implementation. Approaches: Healthcare records have been retrospectively reviewed for the years 2014019. Patient demographics, indications and form of anticoagulants, INR range, days on anticoagulation, TTR, TTR and compliance have been obtained. Percentage TTR was calculated by Rosendaal linear interpolation method. Bleeding complications were defined as outlined by the ISTH-SSC for non-surgical patients. NewInstituto Nacional de Cardiologia ‘Ignacio Chavez’, Mexico, Mexico; Grupo Cooperativo Latinoamericano de Hemostasis y Trombosis, Clinical Hospital University of Chile, Santiago, Chile; 5Hospital deMexico, Mexico; 3Cl ica 25 de Mayo, Mar del Plata, Argentina;Cl icas, Facultad de Medicina, Montevideo, Uruguay Background: A Latin American Group (Argentina, Chile, Mexico, Uruguay) for Laboratory Study of Direct Oral Anticoagulants (DOACs), Caspase 7 Inhibitor Synonyms Larila, was developed in January 2019. Analytical, potential, Ethics Committees approved study. Aims: To standardize the laboratory handle of Rivaroxaban and Apixaban in Latin America, to correlate anti Xa activity and coagulation, to register adverse events. Methods: Individuals 18 yo. Non-valvular atrial fibrillation (NVAF) and/or Venous Thromboembolic Disease (VTE) on Rivaroxaban 20